These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10870934)

  • 1. Soluble tumor necrosis factor alpha receptors (sTNF-Rs) in HIV-1-infected intravenous drug users: change in circulating sTNF-R type II level and survival for AIDS patients.
    Ajello F; La Licata R; Lodato M; Vitale F; Bonura F; Valenti R; Bruno M; Romano N
    Eur J Epidemiol; 2000 Mar; 16(3):209-16. PubMed ID: 10870934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
    Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection.
    Margolick JB; Muñoz A; Vlahov D; Solomon L; Astemborski J; Cohn S; Nelson KE
    JAMA; 1992 Mar; 267(12):1631-6. PubMed ID: 1347321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor alpha and soluble tumor necrosis factor receptors in individuals with human immunodeficiency virus infection.
    Zangerle R; Gallati H; Sarcletti M; Wachter H; Fuchs D
    Immunol Lett; 1994 Jul; 41(2-3):229-34. PubMed ID: 8002043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users.
    Page JB; Lai SH; Chitwood DD; Klimas NG; Smith PC; Fletcher MA
    Lancet; 1990 Jun; 335(8703):1439-41. PubMed ID: 1972217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum levels of soluble tumor necrosis factor receptors as markers for disease progression of human immunodeficiency virus infection].
    Hattori M; Tateyama M; Oishi T; Miyasaka S; Fukutake K
    Rinsho Byori; 1997 Nov; 45(11):1085-90. PubMed ID: 9396350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin and granulocyte-macrophage colony-stimulating factor (GM-CSF) levels in sera of patients with HIV infection.
    Reddy MM; Grieco MH
    Int J STD AIDS; 1991; 2(2):128-32. PubMed ID: 2043705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble receptors for tumour necrosis factor: a putative marker of disease progression in HIV infection.
    Godfried MH; van der Poll T; Jansen J; Romijin JA; Schattenkerk JK; Endert E; van Deventer SJ; Sauerwein HP
    AIDS; 1993 Jan; 7(1):33-6. PubMed ID: 8382926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of Circulating Soluble Tumor Necrosis Factor-α Receptors 1 and 2 with Interleukin-6 Levels in an Aging Cohort of Injection Drug Users with or at High Risk for HIV Infection.
    Leng SX; Dandorf S; Li H; Carlson J; Hui J; Mehta SH; Piggott D; Islam S; Manwani B; Kirk GD
    AIDS Res Hum Retroviruses; 2015 Dec; 31(12):1257-64. PubMed ID: 26414536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble receptors for tumor necrosis factor are markers for clinical course but not for major metabolic changes in human immunodeficiency virus infection.
    Godfried MH; Romijn JA; van der Poll T; Weverling GJ; Corssmit EP; Endert E; Eeftinck Schattenkerk JK; Sauerwein HP
    Metabolism; 1995 Dec; 44(12):1564-9. PubMed ID: 8786725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
    Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
    Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection.
    Godfried MH; van der Poll T; Weverling GJ; Mulder JW; Jansen J; van Deventer SJ; Sauerwein HP
    J Infect Dis; 1994 Apr; 169(4):739-45. PubMed ID: 7907641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HTLV-II/HIV-1 coinfection and risk for progression to AIDS among intravenous drug users.
    Visconti A; Visconti L; Bellocco R; Binkin N; Colucci G; Vernocchi L; Amendola M; Ciaci D
    J Acquir Immune Defic Syndr (1988); 1993 Nov; 6(11):1228-37. PubMed ID: 7901382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low serum thiol levels predict shorter times-to-death among HIV-infected injecting drug users.
    Marmor M; Alcabes P; Titus S; Frenkel K; Krasinski K; Penn A; Pero RW
    AIDS; 1997 Sep; 11(11):1389-93. PubMed ID: 9302450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis.
    Glossop JR; Dawes PT; Nixon NB; Mattey DL
    Arthritis Res Ther; 2005; 7(6):R1227-34. PubMed ID: 16277675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters.
    Aukrust P; Liabakk NB; Müller F; Lien E; Espevik T; Frøland SS
    J Infect Dis; 1994 Feb; 169(2):420-4. PubMed ID: 7906293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered concentrations of appetite regulators may contribute to the development and maintenance of HIV-associated wasting.
    Arnalich F; Martinez P; Hernanz A; González J; Plaza MA; Montiel C; Peña JM; Vázquez JJ
    AIDS; 1997 Jul; 11(9):1129-34. PubMed ID: 9233460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of immune activation with intravenous heroin use and methadone treatment in HIV-1 seropositive and seronegative subjects.
    Di Franco MJ; Marlink R; Hunter DJ; Tosteson T; Mayer K; Essex M
    J Acquir Immune Defic Syndr (1988); 1993 Dec; 6(12):1297-300. PubMed ID: 8254465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals.
    Zangerle R; Steinhuber S; Sarcletti M; Dierich MP; Wachter H; Fuchs D; Möst J
    Int Arch Allergy Immunol; 1998 Jul; 116(3):228-39. PubMed ID: 9693271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum beta 2-microglobulin in intravenous drug users and its correlation with human immunodeficiency virus infection.
    Chironna M; Fanelli M; Potenza D; Serio G; Quarto M
    Int J Clin Lab Res; 1994; 24(2):90-3. PubMed ID: 7919434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.